The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | New therapeutic targets in CLL: ROR1
The identification of novel therapeutic targets is essential for the improved treatment of hematological cancer, particularly due to the development of drug resistance. Here, Constantine Tam, MD, FRACP, FRCPA, of Peter MacCallum Cancer Centre, Melbourne, Australia, discusses a new therapeutic target in the field of chronic lymphocytic leukemia (CLL): ROR1. Dr Tam highlights the promising results of an early phase study of an ROR1-directed monoclonal antibody, as well as what the results of this study can tell us about this target and future therapy development. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
